|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:activities
|
protein synthesis
|
|
gptkbp:advocates_for
|
increasing
|
|
gptkbp:analyzes
|
addressing heterogeneity
|
|
gptkbp:approves
|
regulatory agencies
|
|
gptkbp:benefits
|
storage requirements
rapid development
no live virus
|
|
gptkbp:challenges
|
manufacturing scale-up
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
solid tumors
hematological malignancies
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
|
|
gptkbp:community
|
supportive
|
|
gptkbp:delivers
|
genetic instructions
|
|
gptkbp:developed_by
|
biotechnology companies
|
|
gptkbp:education
|
important
|
|
gptkbp:example
|
gptkb:Moderna's_m_RNA-4157
Bio N Tech's BN T111
|
|
gptkbp:first_introduced
|
COVID-19 vaccines
|
|
gptkbp:future_plans
|
combination therapies
personalized treatment
vaccine optimization
|
|
gptkbp:healthcare
|
gptkb:significant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
m RNA cancer vaccine
|
|
gptkbp:impact
|
cancer mortality
|
|
gptkbp:innovation
|
cancer immunotherapy
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_compared_to
|
traditional vaccines
|
|
gptkbp:is_effective_against
|
promising results
|
|
gptkbp:is_tested_for
|
under investigation
|
|
gptkbp:population
|
varied
|
|
gptkbp:produced_by
|
gptkb:launch_complex
antigens
|
|
gptkbp:public_perception
|
growing interest
|
|
gptkbp:ram
|
long-lasting
|
|
gptkbp:receives_funding_from
|
gptkb:Company
government grants
private investment
|
|
gptkbp:regulatory_body
|
fast track designation
|
|
gptkbp:regulatory_compliance
|
conditional
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
oncology
|
|
gptkbp:research_focus
|
tumor-specific antigens
|
|
gptkbp:responds_to
|
variable
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:sales
|
expanding
|
|
gptkbp:shipping_options
|
lipid nanoparticles
|
|
gptkbp:side_effect
|
mild to moderate
|
|
gptkbp:student_enrollment
|
ongoing
|
|
gptkbp:supply_chain
|
critical
|
|
gptkbp:targets
|
cancer cells
|
|
gptkbp:technology
|
nucleic acid vaccines
|
|
gptkbp:treatment
|
checkpoint inhibitors
under analysis
|
|
gptkbp:trigger_type
|
immune response
|
|
gptkbp:uses
|
messenger RNA
|
|
gptkbp:bfsParent
|
gptkb:Cure_Vac_Biologics
gptkb:Cure_Vac_Inc.
|
|
gptkbp:bfsLayer
|
5
|